NasdaqGM:AUPHBiotechs
A Look At Aurinia Pharmaceuticals (AUPH) Valuation After Strong Growth And Optimistic 2026 Guidance
Aurinia Pharmaceuticals (AUPH) just paired a strong 2025 earnings release with fresh 2026 guidance, outlining expectations for total revenue of US$315 million to US$325 million and net product sales of US$305 million to US$315 million.
See our latest analysis for Aurinia Pharmaceuticals.
At a share price of US$14.80, Aurinia’s recent 1 day share price return of 2.99% and 7 day share price return of 4.59% follow the 1 year total shareholder return of 78.53%. This comes even though the 90 day...